OTC drug for heartburn as good a Rx agent costing 10 times more, US study finds

29 January 2007

A widely available non-prescription drug - Prilosec (omeprazole) OTC - is as effective a treatment for heartburn and acid reflux disease as prescription drugs costing almost 10 times more, according to an analysis from the USA's Consumer Reports Best Buy Drugs, a public education project of the Consumers Union.

"Many people with heartburn and acid reflux could save $1,000 to $2,000 a year by taking an over-the-counter drug that's just as effective as high-priced prescription drugs," stated Gail Shearer, director of the Consumer Reports Best Buy Drugs project. "These are dramatic savings, and illustrate why consumers should talk to their doctors about identifying effective, lower-cost medicines," Ms Shearer added.

Prilosec OTC costs $19-$26 a month on average nationwide, and can be even cheaper at large discount stores. In contrast, the drug Nexium (esomeprazole) - heavily advertised to both consumers and doctors - costs $181-$193 a month on average, depending on dose. Similarly, the study found, Prevacid (lansoprazole) is $131-$186 a month. Both these medicines may cost somewhat less at large discount stores.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight